Document is current
Any future updates will be listed below
-
Authors
Zhao, Liyuan
Tang, Yiwen
Wu, Bingbing
Gao, Yan
Shen, Xi
Liu, Zhenghao
Xiao, Shuyu
Yao, Sanqiao
Li, Jinlong
Shen, Fuhai https://orcid.org/0000-0003-3534-8958
-
Funding
Funding for this research was provided by:
Innovative Research Group Project of the National Natural Science Foundation of China (U21A20334)
Natural Science Foundation of Hebei Province (H2024209027)
- License Information
-
More Information
Article History
Received: 14 March 2025
Accepted: 28 August 2025
First Online: 29 September 2025
Declarations
:
: The animal research protocol was reviewed and approved by the Ethics Committee for Laboratory Animal Welfare of North China University of Science and Technology (SQ-20230060; Title: Prevention and treatment of neonatal umbilical cord mesenchymal stem cell derived exosomes on pulmonary fibrosis in mice; Date of approval: March 8, 2023). The manuscript adhered to the ARRIVE guidelines for the reporting of animal experiments. All animal experiments were carefully performed to avoid animal suffering. The original source of human umbilical cord mesenchymal stem cells (Han’s United Biotechnology Co., Ltd.) has confirmed that there was initial ethical approval for collection of human cells, and that the donors had signed informed consent. The original source of human cells (THP-1) (Ripart Biotechnology Co., Ltd., Hebei) has confirmed that there was initial ethical approval for collection of human cells, and that the donors had signed informed consent.
: Not applicable.
: The authors declare no competing interests.
